The Effects of Vasopressin on Attention Control

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Drug: Placebo; Drug: Vasopressin

• Registration Number: NCT04493554
• Lead Sponsor: University of Electronic Science and Technology of China

Brief Summary

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) could influence attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Detailed Description

A number of previous studies have reported vasopressin's effect on human social behavior and social cognition, although it remains unclear whether vasopressin could modulate attention allocation including stimulus-driven bottom-up control and goal-directed top-down control. In the current randomized, between-subject, placebo controlled study, 89 healthy male subjects will be recruited and receive either vasopressin (20 IU) or placebo control administered intranasally. 45 minutes after treatment subjects will be required to complete a social-emotional saccade /antisaccade eye-tracking paradigm. The paradigm uses social (happy, sad, angry, fear, and neutral faces) as well as non-social (oval shapes) stimuli to explore social- and emotion-specific effects of vasopressin.

Study Timeline

• Study First Submitted: 2020-07-27
• Study First Submitted QC: 2020-07-27
• Study Start: 2020-07-28
• Study First Posted: 2020-07-30
• Primary Completion: 2020-11-30
• Status Verified: 2021-01
• Study Completion: 2021-01-01
• Last Update Submitted: 2021-01-05
• Last Update Posted: 2021-01-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 89

Inclusion Criteria

• Healthy participants
• Non smokers

Exclusion Criteria

• Previous or current medical, psychiatric, neurological disorder
• Regular medication
• Use of any psychoactive substances in the 24 hours before experiment
• Contra-indications for vasopressin
• Contra-indications for eye-tracking data acquisition

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo intranasally
Vasopressin	Vasopressin	Vasopressin (20 IU) intranasally

Primary Outcome Measures

Name	Time	Method
Effect of vasopressin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli	45 minutes - 100 minutes after treatment	Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions
Effect of vasopressin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli	45 minutes - 100 minutes after treatment	Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions

Secondary Outcome Measures

Name	Time	Method
Emotion-specific effects of vasopressin administration on saccade/antisaccade error rates for the separate facial emotions	45 minutes - 100 minutes after treatment	Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin and placebo treatment conditions
Emotion-specific effects of vasopressin administration on saccade/antisaccade latencies towards the separate facial emotions	45 minutes - 100 minutes after treatment	Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions

Trial Locations

Locations (1)

University of Electronic Science and Technology of China(UESTC); 🇨🇳 Chengdu, Sichuan, China